3.60
+0(+0.00%)
Currency In USD
| Previous Close | 3.6 |
| Open | 3.57 |
| Day High | 3.66 |
| Day Low | 3.54 |
| 52-Week High | 4.14 |
| 52-Week Low | 2.46 |
| Volume | 384,102 |
| Average Volume | 439,427 |
| Market Cap | 308.09M |
| PE | -2.18 |
| EPS | -1.65 |
| Moving Average 50 Days | 3.04 |
| Moving Average 200 Days | 3.18 |
| Change | 0 |
If you invested $1000 in Atea Pharmaceuticals, Inc. (AVIR) since IPO date, it would be worth $118.66 as of July 02, 2025 at a share price of $3.6. Whereas If you bought $1000 worth of Atea Pharmaceuticals, Inc. (AVIR) shares 3 years ago, it would be worth $480.64 as of July 02, 2025 at a share price of $3.6.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing of First Patient in C-FORWARD Outside North America
GlobeNewswire Inc.
Jun 24, 2025 11:00 AM GMT
C-FORWARD is the Second Phase 3 Trial in the Global HCV Development Program; the First Phase 3 Trial, C-BEYOND, is Currently Enrolling Patients in the US and Canada Regimen has Potential Best-in-Class Profile with Short Treatment Duration, Low Risk f
Atea Pharmaceuticals Announces Full Results from Phase 2 Study of Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus (HCV) Presented at EASL Congress 2025
GlobeNewswire Inc.
May 07, 2025 11:00 AM GMT
Full Results from Phase 2 Study Confirmed 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Short 8-Week Treatment Duration for Regimen Results from Phase 1 Study Showed Low Risk for Drug-Drug Interactions with Regimen
Atea Pharmaceuticals to Host Virtual HCV KOL Panel on May 14, 2025
GlobeNewswire Inc.
May 01, 2025 11:00 AM GMT
Panel to Discuss Current Challenges Encountered by Patients with HCV, Results from Atea’s Phase 2 Study of the Regimen of Bemnifosbuvir and Ruzasvir, and What a New Optimized HCV Therapy Could Provide for Prescribers and Patients Event to Replace Ate